ACM
RAPP

Aster Capital Management’s Rapport Therapeutics RAPP Stock Holding History

Aster Capital Management’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.5K Buy
+108
New +$3.97K ﹤0.01% 734
2026
Q1 		– Sell
-300
Closed -$9.1K – 1413
2025
Q4 		$9.1K Buy
+300
New +$8.3K ﹤0.01% 760
2025
Q1 		– Sell
-5
Closed -$89 – 1735
2024
Q4 		$89 Buy
+5
New +$111 ﹤0.01% 1072

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Aster Capital Management's RAPP Position: Q2 2026 in Review

Aster Capital Management opened a new position in Rapport Therapeutics (RAPP) in Q2 2026: 108 shares worth $4.5K. The stake represents ﹤0.01% of the portfolio and ranks #734 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in RAPP as recently as Q4 2025.

Aster Capital Management first reported a position in RAPP in Q4 2024 and has held it in 3 quarters since. The position peaked at $9.1K in Q4 2025. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Aster Capital Management held 108 shares of Rapport Therapeutics worth $4.5K as of Q2 2026.
  • Rapport Therapeutics was a new Aster Capital Management position in Q2 2026.
  • Rapport Therapeutics made up ﹤0.01% of Aster Capital Management's portfolio in Q2 2026, its #734 holding.
  • Aster Capital Management first reported a position in Rapport Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Aster Capital Management's Rapport Therapeutics position peaked at $9.1K in Q4 2025.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.